Evidence map›Paper›PMID 36549012›Full record

ArticleHead & neck2023

Ninety-day mortality following transoral robotic surgery or radiation at Commission on Cancer-accredited facilities.

James R Janopaul-Naylor, Manali Rupji, Rachel A Tobillo, Joshua W Lorenz, Jeffrey M Switchenko, Sibo Tian, Azeem S Kaka, David C Qian, Ashley J Schlafstein, Conor E Steuer and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

James R Janopaul-NaylorDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-3612-4852
Manali RupjiBiostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Rachel A TobilloDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
Joshua W LorenzDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
Jeffrey M SwitchenkoBiostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Sibo TianDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-5018-4854
Azeem S KakaDepartment of Otolaryngology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
David C QianDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
Ashley J SchlafsteinDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
Conor E SteuerDepartment of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
Jill S RemickDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
Soumon RudraDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
Mark W McDonaldDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.ORCID 0000-0003-3021-9356
Nabil F SabaDepartment of Otolaryngology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.ORCID 0000-0003-4972-1477
William A StokesDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.
Mihir R PatelDepartment of Otolaryngology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-6477-9728
James E BatesDepartment of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, Georgia, USA.

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292
6 · The paper itself

Abstract

backgroundPostoperative mortality for oropharynx squamous cell carcinoma (OPSCC) with transoral robotic surgery (TORS) varies from 0.2% to 6.5% on trials; the real-world rate is unknown.

methodsNCDB study from 2010 to 2017 for patients with cT1-2N0-2M0 OPSCC with Charleson-Deyo score 0-1. Ninety-day mortality assessed from start and end of treatment at Commission on Cancer-accredited facilities.

results3639 patients were treated with TORS and 1937 with radiotherapy. TORS cohort had more women and higher income, was younger, more often treated at academic centers, and more likely to have private insurance (all p < 0.05). Ninety-day mortality was 1.3% with TORS and 0.7% or 1.4% from start or end of radiotherapy, respectively. From end of therapy, there was no significant difference on MVA between treatment modality.

conclusionsThere is minimal difference between 90-day mortality in patients treated with TORS or radiotherapy for early-stage OPSCC. While overall rates are low, for patients with expectation of cure, work is needed to identify optimal treatment.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsOropharyngeal NeoplasmsRobotic Surgical ProceduresFemaleHumansSquamous Cell Carcinoma of Head and Neck90-day mortalityorgan preservationoropharynx cancerpostoperative mortalityradiotherapytransoral robotic surgery

Identifiers

PMID36549012
PMCPMC9898134

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.